Our AbbVie (NYSE:ABBV | ABBV Price Prediction) call lands on the constructive side of the ledger after a noisy but encouraging Q1 earnings report. The 24/7 Wall St. price target for AbbVie…
Vandita Jadeja Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices except the Nasdaq end lower, with the Nasdaq closing virtually unchanged at…
Income investors shopping the healthcare aisle often land on Gabelli Healthcare & WellnessRx Trust (NYSE:GRX), a closed-end fund managed by Gabelli Funds that has quietly paid quarterly distributions for more than 14…
Market volatility in 2026 has reminded investors that earned income alone is fragile. When tariff fears rattle equities and economic uncertainty clouds the outlook, dividend investors sleep better. Passive income from dividend…
Gabelli Dividend & Income Trust (NYSE:GDV) trades near $29 and pays a $0.15 monthly distribution, up from $0.11 per month in 2024 to $0.14 in 2025 to $0.15 starting January 2026. At…
One of Wall Street’s top firms just made the bull case for AbbVie (NYSE:ABBV | ABBV Price Prediction) stock, initiating coverage with a Buy rating and a $262 price target. Canaccord calls…
David Moadel AbbVie (NYSE:ABBV | ABBV Price Prediction) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The stock is down 7.03% year-to-date as of mid-April 2026, sitting at $208.99,…
Vandita Jadeja AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth quarter earnings in early February. AbbVie posted record net sales with revenue up 10% year over year, powered by a…
AbbVie (NYSE:ABBV | ABBV Price Prediction) stock has pulled back 12% over the past month, sliding to around $204. JPMorgan isn’t running from that weakness — it’s calling it a buying opportunity,…
Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two very different pharmaceutical stories. AbbVie is riding a post-Humira reinvention, while Pfizer…
With inflation back in the economic picture, simply getting a dependable income stream may not be the best strategy for Boomer and Gen X retirees. Without some degree of growth, portfolios built…
Retirees and income-focused investors have long used Vanguard Value ETF (NYSEARCA:VTV) as a core portfolio anchor, drawn to its dividend income, lower volatility relative to growth funds, and near-zero cost structure. When…
Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT), a pure-play sector fund that has quietly compounded wealth for long-term investors…
A 1.5% yield sounds unimpressive until you realize the dividend check doubles roughly every seven years. That is the premise behind the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG): skip the high-yield traps and…
Growth investing has had a choppy start to 2026. The major growth benchmarks are down in the low single digits year-to-date, and some of the biggest names in tech have pulled back…
